Full Text View
Tabular View
No Study Results Posted
Related Studies
OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis
This study has been completed.
Study NCT00449722   Information provided by Dr. Falk Pharma GmbH

First Received on March 20, 2007.   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ulcerative Colitis
Additional conditions recognized in this trial
Colitis
Colitis, Ulcerative
Ulcer
More general conditions related to this trial
Colonic Diseases
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Pathologic Processes
Interventions listed in this trial
mesalazine
Additional drug interventions recognized in this trial
Mesalamine
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Dr. Falk Pharma GmbH


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services